What is ivWatch?
Founded in 2010 and headquartered in Newport News, Virginia, ivWatch is at the forefront of developing advanced biosensor technology. The company's core mission is to enhance patient safety and optimize the efficacy of intravenous (IV) therapy. By providing real-time monitoring and alerts, ivWatch aims to prevent adverse events associated with IV treatments, thereby improving patient outcomes and reducing healthcare costs. Their technology addresses critical needs within the healthcare sector, positioning them as a key player in medical device innovation.
How much funding has ivWatch raised?
ivWatch has raised a total of $36.9M across 8 funding rounds:
Private Equity
$2.7M
Private Equity
$2.8M
Private Equity
$668K
Private Equity
$12.8M
Private Equity
$14.8M
Private Equity
$2M
Debt
$350K
Debt
$778K
Private Equity (2011): $2.7M, investors not publicly disclosed
Private Equity (2012): $2.8M, investors not publicly disclosed
Private Equity (2014): $668K, investors not publicly disclosed
Private Equity (2015): $12.8M, investors not publicly disclosed
Private Equity (2017): $14.8M, investors not publicly disclosed
Private Equity (2017): $2M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Debt (2021): $778K supported by PPP
Key Investors in ivWatch
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for ivWatch?
The recent major strategic investment signals a pivotal phase for ivWatch, likely enabling the company to accelerate its product development, expand its market reach, and further enhance its technological capabilities. This infusion of capital is expected to fuel strategic initiatives aimed at solidifying its position in the competitive medical technology landscape. Future growth may involve scaling operations, forging new partnerships, and continuing to innovate in the realm of patient monitoring to address evolving healthcare challenges.
See full ivWatch company page
